Table 2. Tumor Delivery Efficiency of Peptide (or Common Antibody)-Targeted Nanomaterialsa.
| cancer type | material | shape | hydrodynamic diameter (nm) | peptide on surface | peptide target | tumor uptake (%id/g) | np composition | year | ref |
|---|---|---|---|---|---|---|---|---|---|
| Breast Cancer | |||||||||
| nurine breast cancer (4T1) | silica | spherical | 194 | TRC105 | CD105 | 9.9 (4 h) | hollow MSN HMSN-ZW800-TRC105 | 2014 | (414) |
| murine breast cancer (4T1) | silica | spherical | 175 | TRC105 | CD105 | 5.4 (4 h) | multifunctional MSN 64Cu-MSN-800CW-TRC105(Fab) (dual ligand) | 2014 | (415) |
| murine breast cancer (4T1) | silica | spherical | 168 | TRC105 | CD105 | 5.9 (5 h) | DOX-loaded 64Cu-NOTA-mSiO2-PEG-TRC105 | 2013 | (416) |
| murine breast cancer (4T1) | CuS NP encapsulated in mesoporous silica shells | spherical | 155 | TRC105 | CD105 | 6.0 (24 h) | 64Cu-CuS@MSN-TRC105 | 2015 | (417) |
| murine breast cancer (4T1) | zinc oxide | spherical | 101 | TRC105 | CD105 | 6.4 (0.5 h) | (64Cu-)NOTA-ZnO-PEG-TRC105 | 2015 | (418) |
| murine breast cancer (4T1) | polymeric | spherical | 37 | TRC105 | CD105 | 5.7 (5 h) | PAMAM-PLA-b-PEG-TRC105 | 2013 | (419) |
| murine breast cancer (4T1) | graphene oxide | flake | 37 | TRC105 | CD105 | 5.7 (6 h) | 64Cu-NOTA-RGO-TRC105 | 2013 | (420) |
| murine breast cancer (4T1) | graphene oxide | flake | 27 | TRC105 | CD105 | 5.8 (0.5 h) | NOTA-GO-TRC105 | 2012 | (421) |
| murine breast cancer (4T1) | graphene | flake | 27 | TRC105 | CD105 | 5.8 (7 h) | 66Ga-NOTA-GO-TRC105 | 2012 | (422) |
| murine breast cancer (4T1) | hyaluronic hydrogel | spherical | 226 | hyaluronic acid | CD44 receptor | 1.3 | HA-HPCD/ADA-PEG | 2015 | (423) |
| murine breast cancer (4T1) | polymeric | spherical | 71 | folic acid | folate receptor | 13.9 (6 h) | FA-functionalized DOX-conjugated micelles (FA-PEG-b-PCL-hyd-DOX) | 2013 | (424) |
| murine breast cancer (4T1) | quantum dots | spherical | 14 | CGKRK | p32 (gC1qR or HABP) | 7.3 (24 h) | QD-CGKRK (64Cu-QD-OCH3) | 2019 | (425) |
| murine breast cancer (4T1) | iron oxide | spherical | 51 | human serum albumine | gp60 receptor (albondin) and SPARC | 3.25 (1 h) | D-HINPs (DOX-loaded HINPs) | 2011 | (426) |
| murine breast cancer (Cl-66) | polymeric | spherical | 23 | cRGD | integrin α(v)β3 | 6.0 | cyclic RGD-DOX-nanoparticle (NP) | 2005 | (427) |
| human breast cancer (MDA-MB-231) | liposomes | spherical | 121 | hyaluronic acid | CD44 receptor | 2.0 (24 h) | HA-liposomes-PEG | 2014 | (428) |
| human breast cancer (MDA-MB-231) | polymeric | spherical | 91 | F3 | cellular nucleolin | 6.1 (24 h) | PAMAM-DOX-F3 | 2018 | (429) |
| human breast cancer (MDA-MB-231) | polymeric | spherical | 274 | folic acid | folate receptor | 0.1 | ICG loaded FA-PLGA and mPEG-PLGA (dual modified NP) | 2012 | (430) |
| human breast cancer (MDA-MB-231) | gold | star | 68 | aptamer AS1411 | NCL (shuttle protein nucleolin) | 3.1 | Apt-AuNS | 2015 | (431) |
| human breast cancer (MDA-MB-435) | gold | spherical | 60 | transferrin | transferrin receptor (CD71) | 20.0 | AuNP | 2014 | (432) |
| human breast cancer (MDA-MB-435) | iron oxide | nanoworm | 70 length and 30 thickness | CREKA | clotted plasma proteins in the blood vessels and stroma of tumors | 5.3 (24 h) | NW-C (NW-P175-C) | 2009 | (433) |
| human breast cancer (MCF-7/ADR) | hydrogel | spherical | 152–219 | hyaluronic acid | CD44 receptor | 12.5 (10 h) | DOX-loaded HA-Lys-LA X-NP | 2015 | (434) |
| human breast cancer (MCF-7) | polymeric | spherical | 72–80 | hyaluronic acid | CD44 receptor | 8.6 (6 h) | DOX-loaded cross-linked HA-PBLG-LA NP (CLNPs) | 2016 | (435) |
| human breast cancer (MSA-MB-468) | polymeric | spherical | 25 and 60 | EGF | EGFR | 4.1 (MDA 25 nm), 5.1 (MDA 60 nm), 1.6 (MCF-7 25 nm), 3.7 (MCF-7 60 nm) (48 h) | 111In-labeled T-BCM-25/60 | 2010 | (436) |
| human breast cancer (MCF-7) | |||||||||
| human breast cancer (MDA-MB-468) | liposomes | spherical | 80–100 | cetuximab (C225 mAb) | EGFR | 15.4 (72 h) | anti-EGFR immunoliposomes-DOX | 2005 | (437) |
| human breast cancer (MDA-MB-361) | gold | spherical | 54.2 | trastuzumab antibody | HER2 receptor | 29.6 (48 h) | 111In-Au-T | 2012 | (438) |
| human breast cancer (BT474-M3) | liposomes | spherical | 101 | scFv F5 | HER2 receptor | 6.7 (24 h) | 64Cu:4-DEAP-ATSC loaded into PEGylated liposomal DOX (PLD) and HER2-targeted PLD (MM-302) | 2015 | (439) |
| human breast cancer (BT-474) | gold | spherical | 15 | herceptin | HER2 receptor | 8.3 (20 h) | herceptin-AuNPs | 2011 | (440) |
| human breast cancer (BT-474) | liposomes | spherical | 90 | anti-HER Mab fragments | HER2 receptor | 2.8 (24 h) | anti-HER22 immunoliposomes | 2006 | (441) |
| human breast cancer (SUM190) | protein-based | spherical | not reported | biotinylated herceptin | HER2 receptor | 21 (40 h) | Cy5.5/Herceptin/DOTA-111In NP | 2010 | (442) |
| human breast cancer (SkBr3) | iron oxide | spherical | (16) TEM | trastuzumab antibody | HER2 receptor | 12.6 (48 h) | trastuzumab functionalized, DOX-conjugated, 111ln labeled, APTES-PEG coated SPION | 2015 | (443) |
| human breast cancer (NIH3T6.7) | Mn-doped MnFe2O4 | spherical | 6,9,12 | herceptin | HER2 receptor | 3.4 (24 h) | 111ln-labeled MnMEIO-herceptin | 2007 | (444) |
| human breast cancer (HBT 3477) | Iron oxide | spherical | 40 | ChL6 mAb | integral membrane glycoprotein | 13.5 (48 h) | immunoreactive 111In-ChL6bioprobe | 2005 | (445) |
| human breast cancer (HBT 3477) | Hydrogel iron oxide hybrid | spherical | 20 (core size TEM) | ChL6 mAb | membrane glyoprotein | 13.3 (2 days) | 111In-DOTA-ChL6 | 2007 | (446) |
| Glio- and Neuroblastoma | |||||||||
| human glioblastoma (U-87MG) | iron oxide | spherical | 161 | biotin | avidin/streptavidin | 0.6 | MNP-APS-biotin | 2013 | (447) |
| human glioblastoma (U-87MG) | gold | tripod | 24 | RGD | integrin α(v)β3 | 7.9 (24 h) | RGD-Au-tripods | 2014 | (448) |
| human glioblastoma (U-87MG) | iron oxide | spherical | not reported | RGD | integrin α(v)β3 | 5.6 (6 h) | cRGD-conjugated SPIO nanocarriers | 2011 | (449) |
| human glioblastoma (U-87MG) | silica | spherical | 226 | cRGDyK | integrin α(v)β3 | 8.1 (3 h) | 64Cu-NOTA-HMSN-PEG-cRGDyK | 2015 | (450) |
| human glioblastoma (U-87MG) | NaGdF4 | spherical | 32 | cRGDyk | integrin α(v)β3 | 2.8 (4.5 h) | (cRGDyk)(2)-UCNPs | 2013 | (451) |
| human glioblastoma (U-87MG) | quantum dots | spherical | 20 | RGD | integrin α(v)β3 | 4.0 (25 h) | DOTA-QD-RGD | 2007 | (452) |
| human glioblastoma (U-87MG) | single-walled carbon nanotubes | AR 67 rods | 200 × 3 nm2 (AFM) | RGD | integrin α(v)β3 | 12.1 | PEG-RGD-SWNTs | 2007 | (453) |
| human glioblastoma (U-87MG) | dendrimer-entrapped gold NP | spherical | 72 | RGD | integrin α(v)β3 | 0.9 | Gd–Au DENPs-RGD | 2015 | (454) |
| human glioblastoma (U-87MG) | quantum dots | spherical | 19.6 | RGD | integrin α(v)β3 | 10.0 (4 h) | QD800-RGD | 2010 | (455) |
| human glioblastoma (U-87MG) | iron oxide | spherical | 40 | RGD | integrin α(v)β3 | 6.75 (6 h) | 121I-RGD-PEG-MNPs (125I-c(RGDyK) peptide PEGylated Fe@Fe3O4 NP) | 2016 | (456) |
| human glioblastoma (U-87MG) | polymeric | spherical | 50 | RGD | integrin α(v)β3 | 7.7 (8 h) | DOX-loaded (cRGD30-RCCM) micelle | 2017 | (457) |
| human glioblastoma (U-87MG) | copper sulfide | spherical | 49.7 | cRGDfK | integrin α(v)β3 | 10.3 (24 h) | (64Cu)CuS-PEG-c(RGDfK) | 2018 | (458) |
| human glioblastoma (U-87MG) | dendrimers | spherical | 15.6 | cRGD and angiopep-2 | imtegrin α(v)β3 and LRP (low-density lipoprotein receptor-related protein) receptor | 0.5 (24 h) | Den-RGD-Angio | 2012 | (459) |
| human glioblastoma (U-87MG) | liposomes | spherical | 131.3 | RGD and substance P | integrin α(v)β3 and neurokinin-1 receptors | 1.0 (1 h), 1.2 (4 h) | 111In-Hybrid-LP | 2013 | (460) |
| human glioblastoma (U-87MG) | polymeric | spherical | 300 | anti-b-HcG mAb | somatostatin receptor (SSR) | 4.3 | PEG-LuD-NP (PEG-coated-177Lu-DOTATATE-PLGA) | 2016 | (461) |
| human glioblastoma (U-87MG) | silica | spherical | 129 | VEGF | VEGFR | 7.8 (3 h) | 64Cu-NOTA-MSN(SUN)-VEGF121 | 2014 | (462) |
| human glioblastoma (U-87MG) | quantum dots | spherical | 23 | VEGF | VEGFR | 4.16 (24 h) | DOTA-QD-VEGF | 2008 | (463) |
| human glioblastoma (U-87MG) | graphene oxide | flake | 33 | VEGEF121 | VEGFR | 8.2 (3 h) | (64Cu-)GO-VEGF121 | 2015 | (464) |
| rat glioma (9L.E29) | gold | spherical | 42 | EGF peptide | EGFR | 6.0 (24 h) | EGFpep-Au NP-Pc4 | 2015 | (465) |
| murine neuroblastoma (Neuo 2A) | liposomes | spherical | 130 | RGD | integrin α(v)β3 | 5.2 (1 h) | siRNS RGD-PEG-PEI | 2007 | (466) |
| murine glioma (GL261) | carbon nanotubes | tubular | 8–24 | angiopep-2 | LRP-1 | 2 (in brain) (5 min) | ANG-targeted chemically functionalized multiwalled carbon nanotubes (f-MWNTs) | 2016 | (467) |
| murine neuroblastoma (Neuo 2A) | gold | spherical | 70 | transferrin | transferrin receptor | 2.4 (24 h) | Tf-PEG-AuNP | 2010 | (468) |
| Skin Cancer | |||||||||
| human epidermoid carcinoma (A431) | polymeric | spherical | 100 | C225 antibody (cetuximab) | EGFR | <0.1 | MMPU (multifunctional multiblock polyurethanes) nanocarrier | 2013 | (469) |
| human epidermoid carcinoma (A431) | gold | spherical | 37 | C225 antibody | EGFR | 7.4 (24 h) | 111In-labeled DTPA-C225-HAuNS | 2008 | (470) |
| human epidermoid carcinoma (A431) | gold iron oxide heterostructure | spherical | 24 | affibody protein (Ac-Cys-ZEGFR:1907) | EGFR | 4.6 (48 h) | Au-IONPs (64Cu-NOTA-Au-IONP-affibody) | 2013 | (471) |
| human epidermoid carcinoma (A431) | nanobody | nanobody | 15 kDa | 99mTc-7C12 and 99mTc-7D12 | EGFR | 7–12 for 99mTc-7C12 and 4–8 for 99mTc-7D12 (1.5 h) | 99mTc-7C12 and 99mTc-7D12 | 2008 | (472) |
| human epidermoid carcinoma (A431) | gold | spherical | 31 | cetuximab | EGFR | 3.7 (48 h) | AuNPs–PPAA–cetuximab–89Zr | 2013 | (473) |
| human melanoma (M21) | liposomes | spherical | 131.3 | RGD and aubstance P | integrin α(v)β3 and neurokinin-1 receptors | 0.6 (1 h) | 111In-hybrid-LP (M21) | 2013 | (460) |
| human melanoma (M21) | silica | spherical | 7 | cRGDY | integrin α(v)β3 | 2.0 (4 h) | cRGDY-PEG-dots | 2011 | (474) |
| murine melanoma (B16/F10) | gold | spherical | 43 | NDP-MSH | melanocortin type-1 receptor | 12.6 (4 h) | NDP-MSH-PEG-HAuNS | 2009 | (475) |
| murine melanoma (B16F10) | gold | spherical | 12.5 | cRGD | integrin α(v)β3 | 8.7 (4 h) | 198AuNP-RGD | 2019 | (476) |
| murine melanoma (B16) | polymeric | spherical | 150–155 | cRGD | integrin α(v)β3 | 6.13 (6 h) | cRGD20/DOX-SCID-Ms | 2016 | (477) |
| murine skin melanoma (B16–F1) | liposomes | spherical | 356 (p39-Flt-1), 125 (p24-NRP-1 and p47-Lyp-1) | p39-Flt-1, p24-NRP-1, p47-Lyp-1 | VEGFR-1, neuropilin-1, mitochondrial protein p32 (gC1qR) | 3.6 (p39-Flt-1; PE–PEG750), 7.2 (p24-NRP-1; PE–PEG750), 5.0 (p47-Lyp-1; PE–PEG750/2000) (24 h) | DOX-loaded radiolabeled liposomes engrafted with peptides (p39-Flt-1, p24-NRP-1, p47-Lyp-1) | 2011 | (478) |
| canine hemangiosarcoma (cHSA) | polymeric | spherical | <100 | A10 aptamer | PSMA | 8.5 (24 h) | A10 (IR783) doxo-PLA NCs | 2015 | (479) |
| Lung Cancer | |||||||||
| human nonsmall cell lung cancer (A549) | hyaluronic acid hydrogel | spherical | 200 | hyaluronic acid | CD44 receptor | 1.5 (6 h) | HA-ODA/HA-PEG | 2013 | (480) |
| human nonsmall cell lung cancer (A549) | MnO | spherical | 100 | cRGD | integrin α(v)β3 | 45.8 | mPEG&cRGD-g-Pasp@MnO | 2015 | (481) |
| human nonsmall cell lung cancer (A549) | polymeric | spherical | 70 | cRGD | integrin α(v)β3 | 1.2 (1 h) | cRGD-encoded SPPM | 2009 | (482) |
| human lung cancer (H1299 and A549) | magnetite nanocluster | spherical | 85 | RGD | integrin α(v)β3 | 4.7 big and 6.1 nascent tumors (12 h) | RGD-MNC | 2012 | (483) |
| human nonsmall lung carcinoma (A549) | gold | rod shaped | 50–80 | ScFv, ATF (amino terminal fragment), cRGD | ScFv against EGFR, ATF against uPAR, cRGD against avb3 integrin receptor | 1.8 (ScFv), 1.9 (uPAR), 0.5 (avb3) (24 h) | Au NRs | 2010 | (484) |
| human lung cancer (NCI-H460) | protein-based | spherical | 100–125 | RGD | integrin α(v)β3 | 39.49 (24 h), 6.97 (72 h) | RGD-BSA-PCL | 2017 | (485) |
| human lung cancer (NCI-H460) | liposomes | spherical | 120–150 | anisamide | sigma receptor | 76.7 (4 h) | siRNA in targeted NP | 2008 | (486) |
| human nonsmall cell lung cancer (H1975) | solid lipid NP | spherical | 160 | cetuximab | EGFR | 5.06 (24 h) | PtSLNs (PEG-modified surface targeted solid lipid nanoparticles) | 2015 | (487) |
| Ovarian Cancer | |||||||||
| human ovarian cancer (SKOV3) | polymeric | spherical | 105–134 | NR7 peptide | EGFR | 11.1 (24 h) | DOX-loaded peptide-conjugated PLGA–PEG NP | 2012 | (488) |
| human ovarian cancer (SKOV3) | quantum dots | spherical | 19 | anti-HER2 affibody | HER2 receptor | 15 (4 h) | nanoparticle–affibody conjugates (QD800-PEG) | 2011 | (489) |
| human ovarian cancer (SKOV3) | quantum dots | spherical | 12 | RGD | integrin α(v)β3 | 19.7 (4 h) | QD710-dendorn-RGD2 | 2012 | (490) |
| Liver Cancer | |||||||||
| murine hepatocellular carcinoma (H22) | chitosan hydrogel | spherical | 133 | Bj-BPP-9a peptide | B2 receptors | 5.0 (12 h) | Pt-CS-BPP | 2014 | (491) |
| murine hepatocellular carcinoma (H22) | hyaluronic acid hydrogel | spherical | 50 | hyaluronic acid | CD44 receptor | 4.0 (4 h) | DOX-loaded HA nanogels | 2015 | (492) |
| murine hepatocellular carcinoma (H22) | protein-based | spherical | 45.7 | RGD | integrin α(v)β3 | 15 0.1 (24) | RGD-sNPS | 2019 | (493) |
| human hepatocellular carcinoma (HuH7) | polymeric | linear and round | 107.1 | B6 | transferrin receptor | 8 (4 h) | LPEI-PEG-B6/NIS | 2017 | (494) |
| human liver carcinoma (HepG2) | albumin | spherical | 170 | glycyrrhetinic acid (GA) | GA-receptor | 13.6 (1 h) | DOX/GA-rHSA NPs | 2015 | (495) |
| rat hepatocellular carcinoma (HeDe) | polymeric | spherical | 124 | folic acid | folate receptor | 9.62 (2 h) | radiolabeled self-assembled NPs 99mTc-CH/y-PGA-FA-NP | 2013 | (496) |
| Prostate Cancer | |||||||||
| human prostate cancer (PC-3) | PhMV-like NPs (Physalis mottle virus) | spherical | 35.7 | DGEA | integrin α2β1 | 5.5 (10 days) | Gd-Cy5.5-PhMV-DGEA | 2019 | (497) |
| human prostate cancer (PC-3) | iron oxide | spherical | 140 | PSMA inhibitor | PSMA | 4.3 (48 h) | PSMA-targeted BNF NP | 2015 | (498) |
| human prostate cancer (LnCAP) | lipid/polymeric | spherical | 30 | cys-DB (anti-PSMA cysteine-diabody) | PSMA | 15 (19 h) | DOTA-cys-DB-PEG-LNP + DOX-PEG-LNP | 2017 | (499) |
| human prostate cancer (Pca) | polymeric | spherical | 160 | A10 aptamer | PSMA | 1.6 (24 h) | PLGA-b-PEG-b-Apt (NP-Apt-5%) | 2008 | (500) |
| human prostate cancer (DU145) | gold | AR 4.0 rods | 61 × 15 (TEM) | RGDfk | integrin α(v)β3 | 1.3 (48 h) | RGDfK-GNRs | 2011 | (501) |
| human prostate cancer (PC-3M) | polymeric | spherical | 23 | TNYL-RAW (EphB4-binding peptide) | EphB4 | 2.9 (24 h) | TNYL-RAW-CCPM | 2011 | (502) |
| Cervical Carcinoma | |||||||||
| human cervical carcinoma (HeLa) | gold | AR 3.8 Rods | 26 | folic acid | folate receptor | 17.1 (24 h) | FA-AuNRs | 2015 | (503) |
| human cervical carcinoma (HeLa) | gold | spherical | 40–50 | folic acid | folate receptor | 5.1 (6 h) | F-PEG-HAuNs-siRNA | 2010 | (504) |
| human cervical carcinoma (HeLa) | polymeric | spherical | 56 | folate | folate receptor | 1.1 (6 h) | PEG-PnBA-PDMAEMA | 2011 | (505) |
| human cervical carcinoma (HeLa) | copper sulfide | spherical | 88.5 | RGD | integrin α(v)β3 | 16.8 (4 h) | RGD@HCuS(VA) | 2017 | (506) |
| human cervical carcinoma (HeLa) | silica coated Mn3O4 | Spherical | 53 | AS411 aptamer | folate receptor | 6.3 (12 h) | Mn3O4@SiO2(RB)-PEG-Apt | 2013 | (507) |
| murine sarcoma (S-180) | polymeric | spherical | 101.4 | transferrin | transferrin receptor | 0.6 (6 h) | actively targetable nanoparticles (ATN) | 2005 | (508) |
| murine sarcoma (S-180) | fullerene | spherical | 94 | transferrin | transferrin receptor | 0.7 (1 h) | HA-C60-Tf/AS | 2015 | (509) |
| human carcinoma (KB) | polymeric | spherical | 71 | folic acid | folate receptor | 15.1 (1 h) | dendrimer (PAMPAM)-polymer hybrid NPs: PEG–PLA NPs | 2014 | (510) |
| human carcinoma (KB) | liposomes | spherical | 76 | folic acid | folate receptor | 2.4 (24 h) | folate-modified gadolinium lipid-based NPs (F(5000)-Nps) | 2014 | (511) |
| human carcinoma (KB) | iron oxide | spherical | 54 | folic acid | folate receptor | 0.6 (4 h) | folic acid modified maghemite NPs | 2013 | (512) |
| human carcinoma (KB) | polymeric | spherical | 77 | folic acid (PEG and 50% FA) | folate receptor | 6.5 | fol-PEG-p(Asp-Hyd-ADR) | 2007 | (513) |
| human carcinoma (KB) | polymeric | spherical | not reported | folic acid | folate receptor | 5.9 (4 h) | 64Cu-TETA-SCK-folate | 2005 | (514) |
| human carcinoma (KB) | dendrimer | spherical | not reported | folic acid | folate receptor | 6.9 (4 days) | tritiated G5-3H-FA | 2005 | (515) |
| Kidney Cancer | |||||||||
| human renal cell carcinoma (SK-RC-52) | dendrimers | spherical | not reported | RGD | integrin α(v)β3 | 7.27 (2 h) | 111In-labeled tetrameric RGD-dendrimers | 2007 | (516) |
| henal cell carcinoma (OS-RC-2) | liposomes | spherical | 300 | NGR motif peptide | CD13 | 1.4 (24 h) | R4/NGR-PEG-LP (dual-ligand) | 2012 | (517) |
| Colon Cancer | |||||||||
| murine colon adenocarcinoma (C-26) | liposomes | spherical | 225 | transferrin | transferrin receptor | 2.8 | (Tf(+)-PEG-CL liposomes | 2006 | (518) |
| Gastric Cancer | |||||||||
| human gastric cancer (MKN45) | copper sulfide | spherical | 61 | cRGD | integrin α(v)β3 | 23.4 (12 h) | T-MAN (Gd-doped CuS micellar NPs with cRGD and MMP-2-cleavable fluorescent substrate | 2019 | (519) |
| human gastric cancer (MGC-803) | gold | spherical | 6 | folic acid | folate receptor | <0.1 | Ce6@GNCs-PEG2K-FA | 2015 | (520) |
| Pancreatic Cancer | |||||||||
| human pancreatic carcinoma (PANC-1) | gelatin hydrogel | spherical | 231 | EGFR peptide | EGFR | 23.2 (2 h) | SH-Gel PEG peptide | 2013 | (521) |
| Laryngeal Cancer | |||||||||
| human laryngeal squamous cell carcinoma (Tu686) | gold | spherical | 80 | ScFv antibody | EGFR | 8.0 (5 h) | SERS NPs | 2008 | (522) |
| Other | |||||||||
| human fibrosarcoma cells (HT1080) | iron oxide | nanoworm | 70 length and 30 thickness | CREKA | clotted plasma proteins in the blood vessels and stroma of tumors | 5.3 (24 h) | NW-C (NW-P175-C) | 2009 | (433) |
| murine fibroblasts (T6–17) | iron oxide | spherical | 33–35 | Her2 affibody (3.5), LDS affinity peptide (1.3), RGD (1.5) | HER2 receptor, HSP47, avb3 integrin receptor | 1–3.5 (24 h) | SPION | 2014 | (523) |
| Ehrlich ascites tumor (EAT) | liposomes | spherical | 386 | hyaluronic acid | CD44 receptor | 2.4 (2 h) | HA-NLC | 2014 | (524) |
a
Nanomaterial delivery efficiency to solid tumors with targeted peptide coating of the NM, from studies published in 2005–2020. Please note that for this table, only those studies are taken into account where the delivery efficacy of the nanomaterials to the tumors has been determined (i.e. %ID/g). ID/g = injected dose per gram of tissue. The value between brackets indicates the time after injection at which the analysis was performed.